Safety and efficacy of rh-Lactoferrin in Diabetic Ulcers

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 4R44AR049961-02
Agency Tracking Number: AR049961
Amount: $715,265.00
Phase: Phase II
Program: SBIR
Awards Year: 2004
Solitcitation Year: 2004
Solitcitation Topic Code: N/A
Solitcitation Number: PHS2004-2
Small Business Information
AGENNIX, INC.
AGENNIX, INC., 8 GREENWAY PLZ, STE 910, HOUSTON, TX, 77046
Duns: N/A
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 JOSE Engelmayer
 (713) 552-1091
 JENGELMAYER@AGENNIX.COM
Business Contact
Phone: (713) 552-1091
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Research Objectives: Determine the safety, pharmacokinetics, pharmacodynamics, and efficacy of topical recombinant human lactoferrin (rhLF) in promoting healing in diabetic ulcers. There are 7.5 million U

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government